Add BrightSurf on Google Email

Cedars-Sinai Medical Center


The Lancet publishes landmark trial of Duchenne muscular dystrophy therapy

A Phase III clinical trial has demonstrated that a new cell therapy called deramiocel can slow the weakening of skeletal muscles by 54% and preserve heart function, slowing progression of cardiomyopathy. The therapy, based on Marbán's discoveries, takes a different approach from other treatments for Duchenne muscular dystrophy.

SourceCedars-Sinai Medical Center·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJul 29, 2026

How do spinal cord injuries heal?

Researchers at Cedars-Sinai Medical Center have identified a mechanism that could help treat patients with spinal cord injuries, stroke, and neurological conditions. Astrocytes, a type of cell in the central nervous system, play a critical role in responding to damage and disease, sending signals to immune cells to clean up debris resu...

SourceCedars-Sinai Medical Center·JournalNature·DateDec 17, 2025

Artificial intelligence has potential to aid physician decisions during virtual urgent care

A Cedars-Sinai study finds AI treatment recommendations were graded higher than physician decisions in virtual urgent care settings. AI excelled at identifying critical red flags and suggesting antibiotic treatments, but physicians better assessed patient histories and adapted recommendations.

SourceCedars-Sinai Medical Center·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateApr 4, 2025

New Cedars-Sinai study shows how specialized diet can improve gut disorders

A new study from Cedars-Sinai examined the effectiveness of a specialized diet in improving symptoms of gastrointestinal disorders linked to an imbalance in gut microbiota. The research found that most participants reported tolerating the diet well and experienced significant relief from common symptoms like bloating and discomfort.

SourceCedars-Sinai Medical Center·JournalClinical Gastroenterology and Hepatology·TypeRandomized controlled/clinical trial·DateApr 1, 2025

Study: Older adult prostate cancer patients are increasingly being overtreated

A new study by Cedars-Sinai reveals that significant percentages of older men with intermediate- and high-risk prostate cancers are being subjected to aggressive treatments that may not extend their lives, highlighting the need for a more personalized approach to cancer treatment. The study suggests that better estimation, communicatio...

SourceCedars-Sinai Medical Center·JournalJAMA Internal Medicine·TypeObservational study·DateNov 11, 2024

Patterns of intelligence

Researchers identify neural basis for abstraction and inference processes in the human brain, showing coordinated brain cell activity represents learned knowledge. The study used artificial intelligence to extract relevant responses from thousands of brain cells.

SourceCedars-Sinai Medical Center·JournalNature·TypeRandomized controlled/clinical trial·DateAug 14, 2024

Closing in on triple-negative breast cancer

Researchers analyzed cells within triple-negative breast cancer tumors before and after radiation therapy with immunotherapy, identifying three patient groups with distinct responses. The study found that combining radiation therapy and immunotherapy may improve tumor-fighting immune response prior to surgery for some patients.

SourceCedars-Sinai Medical Center·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateJan 8, 2024

An updated look at prostate cancer disparities

A new study finds that systemic therapies for advanced prostate cancer are equally effective for Black men as they are for white men, regardless of socioeconomic status. The research suggests that disparities in healthcare can be eliminated with equal access to treatment.

SourceCedars-Sinai Medical Center·JournalJournal of Clinical Oncology·TypeData/statistical analysis·DateOct 27, 2023

Promising new options for treating aggressive prostate cancer

Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer, improving metastasis-free survival and quality of life. The combination therapy reduced the risk of metastasis or death by 58%, while enzalutamide alone was effective in preventing cancer spread or death.

SourceCedars-Sinai Medical Center·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateOct 18, 2023

Missing a rare cause of hereditary cancer

Researchers identified methylation in normal tissues in some patients with mismatch repair deficiency, leading to undiagnosed Lynch syndrome. This study suggests revising current screening guidelines to include this poorly recognized cause of hereditary cancer.

SourceCedars-Sinai Medical Center·JournalJournal of the National Comprehensive Cancer Network·TypeNews article·DateJul 11, 2023